EffRx Pharmaceuticals
Entry
2018
Hold
5yr
Exit
2023
Who owns EffRx Pharmaceuticals?
EffRx Pharmaceuticals was owned by Sobera Capital through Sobera Capital Fund IV (2017 vintage) from 2018 to 2023, exited via Trade Sale.
Buyer identity available on Pro.
Hand-verified · updated 2026-08-10
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2023
More from Sobera Capital Fund IV
Other portfolio companies in the same fund.
Axellis
Exited 2022
MedTech
United Kingdom· 2018
United Kingdom· 2018M.O.R.E Medical Solutions
Active
MedTech
Germany· 2018
Germany· 2018
Memo Therapeutics
Exited 2026
Biotech
Switzerland· 2018
Switzerland· 2018to
MyoScience
Exited 2019
MedTech
United States· 2018
United States· 2018to
Presidio Pharmaceuticals
Active
PharmaUnited States· 2018
United States· 2018Panoratio
Exited 2021
Data & AnalyticsGermany· 2015
Germany· 2015More PE-backed in Pharma
Comparable pharma deals from other GPs.
Laboratoires Delbert
Active
Socadif
France
France
AMW
Active
SHS Gesellschaft für BeteiligungsmanagementGermany· 2026
Germany· 2026Basic Pharma
Active
SHS Gesellschaft für Beteiligungsmanagement
Netherlands· 2026
Netherlands· 2026
Cinclus Pharma
Active
Claret Capital Partners
Sweden· 2026
Sweden· 2026InfoRLife
Active
BC PartnersSwitzerland· 2026
Switzerland· 2026
IRAB
Active
ARCHIMED
Spain· 2026
Spain· 2026Track EffRx Pharmaceuticals
Save this record to your watchlist and pick up your research where you left off. No spam.
Get the full record on EffRx Pharmaceuticals.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
Already a member? Sign in
Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue